Theranexus
Developing drug combinations that consist of one compound that targets neurons and another that modulates the activity of astrocytes.
Launch date
Employees
Market cap
CAD7.0m
Enterprise valuation
CAD5m (Public information from Sep 2024)
Share price
€0.59 ALTHX.PA
Company register number 791889777
Lyon Auvergne-Rhône-Alpes (HQ)
Financials
Estimates*
| EUR | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| EBITDA | (7.4m) | (5.5m) | (8.7m) | (6.1m) | (7.3m) | (6.9m) | (6.9m) |
| Profit | (5.6m) | (4.8m) | (8.2m) | (6.6m) | (6.8m) | (7.3m) | (7.1m) |
| EV / EBITDA | -0.6x | -11.6x | -1.8x | -0.8x | -1.0x | -2.8x | -3.8x |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
€3.6m | Seed | ||
* | N/A | €20.4m Valuation: €48.4m | IPO |
| N/A | €2.2m | Post IPO Equity | |
* | N/A | Early VC | |
| Total Funding | CAD5.4m | ||
Related Content
Recent News about Theranexus
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.